Morningstar - CBRE GROUP INC (CBRE) We expect CBRE Groups industry-leading platform to create meaningful value for shareholders.

Report

Morningstar

Brad Schwer

EUR 101.80 For Business Accounts Only

We expect CBRE Group's industry-leading platform to create meaningful value for shareholders.

We are placing 16 real estate investment trusts under review as we transfer coverage to a new analyst. Our fair value estimates for CBRE Group, JLL, Apartment Investment and Management, AvalonBay, Equity Residential, Essex Property Trust, HCP, Ventas, Welltower, Host Hotels & Resorts, Realty Income, Federal Realty, Kimco, Simon Property Group, Macerich, and GGP will remain under review until we can publish updated valuations and analyses. We expect to publish new reports for CBRE Group and J...

08/06/2017 14 EN

Underlying

CBRE GROUP INC

CBRE Group is a holding company. Through its subsidiaries, the company is a commercial real estate services and investment firm. The company's segments include: Advisory Services, which provides a range of services globally, including property leasing and capital markets; Global Workplace Solutions, which provides a suite of integrated, contractually-based outsourcing services globally for occupiers of real estate; and Real Estate Investments, which is comprised of investment management services provided globally, development services in the United States and United Kingdom and a service designed to help property occupiers and owners meet the demand for flexible office space solutions on a global basis.

See profile

US12504L1098 New York Stock Exchange United States

Provider

Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

See profile

Analysts

Brad Schwer

Other Reports on these Companies

Vermilion Research

Vermilion Booster Shots: Attractive bottom-fishing stocks

For investors looking for bottom-fishing candidates; stocks that are breaking downtrends, exhibiting ascending reaction lows, and showing stabilizing relative strength.

EUR 42.75

January 5, 2023 January 5, 2023 1 EN

TheScreener

Due to a more favourable environment, CBRE GROUP slightly increases to Neutral

CBRE GROUP (US), a company active in the Real Estate Holding & Development industry, slightly increases its general evaluation. The independent financial analyst theScreener just confirmed the stock market behaviour of the title as moderately risky. At the fundamental level, theScreener confirms the rating of 1 out of 4 stars; given the more favourable environment, the title's overall rating is upgraded to Neutral even if it remains under pressure. As of the analysis date March 18, 2022, the closing price was USD 91.09 and its target price was estimated at USD 84.29.

Free Trial

March 19, 2022 March 19, 2022 1 EN

Vermilion Research

Vermilion Compass: Weekly Equity Strategy

Risk-Off Signals Abating In our last Compass (Dec. 22), we pointed out that despite conflicting signals (some neutral or healthy signals but some risk-off signals as well), our bottom line is that we could not be bearish as long as the Russell 2000 index (IWM) is above $208, the Russell Micro Caps index (IWC) is above $134-$135, and the S&P 500 is above 4495. These support levels have held strong, and we are now seeing the aforementioned risk-off signals starting to abate. This is an encouraging sign and we remain constructive as long as the above support levels hold. Risk-Off Signals Abatin...

EUR 42.75

January 4, 2022 January 4, 2022 1 EN

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Contract manufacturer Lonza reported solid half-year results, with over CHF 2.9 billion in total sales year to date, up about 6.4% from last year and boosted by foreign exchange tailwinds. Core EBITDA margin expanded 30 basis points from last year to about 27.8%, helped slightly by new accounting standards. Management indicated that it continues to expect mid- to high-single-digit sales growth in 2019. We are maintaining our fair value estimate of CHF 210 per share and our no-moat rating. The ph...

EUR 100.00

July 25, 2019 July 25, 2019 13 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

We don't expect any major changes to our AstraZeneca fair value estimate following second-quarter results that largely fell in line with our expectations and slightly ahead of consensus expectations. Overall, the company is posting leading Big Pharma sales growth with total sales up 18% operationally year over year, led by impressive cancer drug sales growth of 57%. Astra's ability to continue to bring next generation drugs to the market that address unmet medical need (especially in oncology) s...

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Damien Conover

Damien Conover

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

EUR 100.00

July 25, 2019 July 25, 2019 14 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

We expect CBRE Group's industry-leading platform to create meaningful value for shareholders.

Vermilion Booster Shots: Attractive bottom-fishing stocks

Due to a more favourable environment, CBRE GROUP slightly increases to Neutral

Vermilion Compass: Weekly Equity Strategy

Business as Usual for No-Moat Lonza; Specialty Ingredients Carve-Out on Track for 2020

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Astra Posts Solid 2Q, Driven by Strong Cancer Drug Sales and Moving Away From One-Time Divestments

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe